After Glenmark’s landmark $2 billion licensing deal with US major AbbVie for its cancer drug, ISB 2001, the stock hit the 10% upper circuit on July 11. But the biggest winners weren’t retail investors …
Mutual funds trump retail in Glenmark surge as cancer drug deal sends stock soaring
view original post